{"id":1651,"date":"2018-10-31T07:49:43","date_gmt":"2018-10-31T07:49:43","guid":{"rendered":"http:\/\/bibliography.nanobiotix.com\/?p=1651"},"modified":"2022-05-24T16:42:47","modified_gmt":"2022-05-24T15:42:47","slug":"2018-astro-2018-phase-iii-nbtxr3-in-soft-tissue-sarcoma","status":"publish","type":"post","link":"https:\/\/bibliography.nanobiotix.com\/fr\/2018-astro-2018-phase-iii-nbtxr3-in-soft-tissue-sarcoma\/","title":{"rendered":"2018 \u2013 ASTRO 2018 \u2013 Phase III NBTXR3 in Soft Tissue Sarcoma"},"content":{"rendered":"<section class=\"wpb-content-wrapper\"><p>[vc_row padding_top=\u00a0\u00bb0&Prime; padding_bottom=\u00a0\u00bb0&Prime; section_container_layout=\u00a0\u00bbfull-width\u00a0\u00bb remove_horizontal_padding=\u00a0\u00bbyes\u00a0\u00bb module_type=\u00a0\u00bbbg-color\u00a0\u00bb gutter_size=\u00a0\u00bbyes\u00a0\u00bb equal_height=\u00a0\u00bbyes\u00a0\u00bb bg_color=\u00a0\u00bb#28282e\u00a0\u00bb][vc_column][vc_row_inner padding_top=\u00a0\u00bb0&Prime; padding_bottom=\u00a0\u00bb0&Prime; gutter_size=\u00a0\u00bbyes\u00a0\u00bb equal_height=\u00a0\u00bbyes\u00a0\u00bb][vc_column_inner column_paddings=\u00a0\u00bb105&Prime; column_position_vertical=\u00a0\u00bbmiddle\u00a0\u00bb column_min_height=\u00a0\u00bb700&Prime; column_min_height_sm=\u00a0\u00bb400&Prime; column_min_height_xs=\u00a0\u00bb350&Prime; module_type=\u00a0\u00bbbg-image\u00a0\u00bb bg_image=\u00a0\u00bb99&Prime; mask_fx=\u00a0\u00bbyes-mask\u00a0\u00bb mask_color_mode=\u00a0\u00bbpalette\u00a0\u00bb mask_bg_color_palette=\u00a0\u00bbmain-mask\u00a0\u00bb animation_fx=\u00a0\u00bbyes-animation\u00a0\u00bb animation_delay=\u00a0\u00bb200&Prime; animation_offset_scroll_down=\u00a0\u00bb90&Prime; width=\u00a0\u00bb1\/2&Prime; animation_in=\u00a0\u00bbfadeInUp\u00a0\u00bb][vc_empty_space height=\u00a0\u00bb60px\u00a0\u00bb responsive_lg=\u00a0\u00bbhidden\u00a0\u00bb responsive_md=\u00a0\u00bbhidden\u00a0\u00bb][az_box_icons box_icon_title=\u00a0\u00bbAuthors\u00a0\u00bb box_icon_color_mode=\u00a0\u00bbon-the-fly\u00a0\u00bb icon_visibility=\u00a0\u00bbyes-icon\u00a0\u00bb icon_type=\u00a0\u00bbfont\u00a0\u00bb icon=\u00a0\u00bbfa fa-edit\u00a0\u00bb icon_color_mode=\u00a0\u00bbon-the-fly\u00a0\u00bb icon_size=\u00a0\u00bb50&Prime; box_icon_color=\u00a0\u00bb#ffffff\u00a0\u00bb icon_color=\u00a0\u00bb#ffffff\u00a0\u00bb]S. Bonvalot<span class=\"notes up\">1<\/span>, P. Rutkowski<span class=\"notes up\">2<\/span>, J. O. Thariat<span class=\"notes up\">3<\/span>, S. Carrere<span class=\"notes up\">4<\/span>, M. P. Sunyach<span class=\"notes up\">5<\/span>, E. Saada<span class=\"notes up\">7<\/span>, P. \u00c1goston<span class=\"notes up\">7<\/span>, A. Hong<span class=\"notes up\">8<\/span>, A. Mervoyer<span class=\"notes up\">9<\/span>, M. Rastrelli<span class=\"notes up\">10<\/span>, C. Le Pechoux<span class=\"notes up\">11<\/span>, V. Moreno<span class=\"notes up\">12<\/span>, R. Li<span class=\"notes up\">13<\/span>, B. Tiangco<span class=\"notes up\">14<\/span>, A. Casado<span class=\"notes up\">15<\/span>, A. Gronchi<span class=\"notes up\">16<\/span>, L. C. Mangel<span class=\"notes up\">17<\/span>, P. Hohenberger<span class=\"notes up\">18<\/span>, M. Delannes<span class=\"notes up\">19<\/span>, Z. Papai<span class=\"notes up\">20<\/span><br \/>\n<span class=\"notes\"><br \/>\n1 \u2013 Institut Curie, Paris, France<br \/>\n2 \u2013 Centrum Onkologii-Instytut im. Sklodowskiej-Curie w Warszawie, Warszawa, Poland<br \/>\n3 \u2013 Centre Baclesse, Caen, France<br \/>\n4 \u2013 Montpellier Cancer Institute, Montpellier, France<br \/>\n5 \u2013 Centre Leon Berard, Lyon, France<br \/>\n6 \u2013 Centre Antoine Lacassagne, Nice, France<br \/>\n7 \u2013 National Institute of Oncology, Budapest, Hungary<br \/>\n8 \u2013 Chris O&rsquo;Brien Lifehouse, Camperdown, Australia<br \/>\n9 \u2013 Institut de Cancerologie de l&rsquo;Ouest-Rene Gauducheau, Saint-Herblain, France<br \/>\n10 \u2013 Istituto Oncologico Veneto IRCCS, Padova, Italy<br \/>\n11 \u2013 Institut Gustave Roussy, Villejuif, France<br \/>\n12 \u2013 Hospital Fundaci\u00f3n Jimenez Diaz, Madrid, Spain<br \/>\n13 \u2013 St. Luke\u2019s Medical Center, Quezon City, Philippines<br \/>\n14 \u2013 The Medical City Cancer Center, Pasay City, Philippines<br \/>\n15 \u2013 Hospital Clinico Universitario San Carlos, Madrid, Spain<br \/>\n16 \u2013 Istituto Nazionale Tumori, Milan, Italy<br \/>\n17 \u2013 Pecs University, Pecs, Hungary<br \/>\n18 \u2013 Universit\u00e4tsklinikum Mannheim, Mannheim, Germany<br \/>\n19 \u2013 Institut Claudius Regaud, Toulouse, France<br \/>\n20 \u2013 Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary<br \/>\n<\/span>[\/az_box_icons][vc_empty_space height=\u00a0\u00bb60px\u00a0\u00bb responsive_lg=\u00a0\u00bbhidden\u00a0\u00bb responsive_md=\u00a0\u00bbhidden\u00a0\u00bb][\/vc_column_inner][vc_column_inner column_paddings=\u00a0\u00bb105&Prime; column_position_vertical=\u00a0\u00bbmiddle\u00a0\u00bb module_type=\u00a0\u00bbbg-color\u00a0\u00bb animation_fx=\u00a0\u00bbyes-animation\u00a0\u00bb animation_delay=\u00a0\u00bb300&Prime; animation_offset_scroll_down=\u00a0\u00bb90&Prime; width=\u00a0\u00bb1\/2&Prime; bg_color=\u00a0\u00bb#ffffff\u00a0\u00bb animation_in=\u00a0\u00bbfadeInUp\u00a0\u00bb][vc_empty_space height=\u00a0\u00bb60px\u00a0\u00bb responsive_lg=\u00a0\u00bbhidden\u00a0\u00bb responsive_md=\u00a0\u00bbhidden\u00a0\u00bb][az_box_icons box_icon_title=\u00a0\u00bbSummary\u00a0\u00bb icon_visibility=\u00a0\u00bbyes-icon\u00a0\u00bb icon_type=\u00a0\u00bbfont\u00a0\u00bb icon=\u00a0\u00bbaz-icon az-icon-layers2&Prime; icon_color_mode=\u00a0\u00bbon-the-fly\u00a0\u00bb icon_color=\u00a0\u00bb#28282e\u00a0\u00bb icon_size=\u00a0\u00bb50&Prime;]A subset of soft tissue sarcoma (STS) patients achieve significant therapeutic benefit from preoperative radiotherapy (RT). Yet, this treatment paradigm may be associated with limited efficacy and increased toxicity, highlighting the necessity of novel multimodal therapies aimed at local control with few adverse events (AEs). NBTXR3 is a first-in-class Hafnium-Oxide nanoparticle. Designed for cancer cell uptake, it is injected intratumorally (IT) and activated by ionizing radiation to yield a tumor-localized high energy deposit and increased cell death compared to the same dose of RT alone. We report now the first phase II\/III randomized clinical trial of NBTXR3 given as preoperative treatment to patients with locally advanced STS of the extremity and trunk wall.<\/p>\n<p>This trial met its primary and secondary endpoints of pCRR and R0 rates, respectively. NBTXR3 with RT demonstrated an acceptable safety profile compared to RT alone. As pCR is a known indicator of long-term treatment response with a positive correlation to both progression free and overall survival, NBTXR3 represent a new option for preoperative treatment for locally advanced STS.[\/az_box_icons][vc_empty_space height=\u00a0\u00bb60px\u00a0\u00bb responsive_lg=\u00a0\u00bbhidden\u00a0\u00bb responsive_md=\u00a0\u00bbhidden\u00a0\u00bb][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/section>","protected":false},"excerpt":{"rendered":"<p>A subset of soft tissue sarcoma (STS) patients achieve significant therapeutic benefit from preoperative radiotherapy (RT). Yet, this treatment paradigm may be associated with limited efficacy and increased toxicity, highlighting the necessity of novel multimodal therapies aimed at local control with few adverse events (AEs). NBTXR3 is a first-in-class Hafnium-Oxide nanoparticle. [\u2026]<\/p>\n","protected":false},"author":1,"featured_media":1623,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[182,183,674],"tags":[500,514,342,510,515,512,334],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/posts\/1651"}],"collection":[{"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/comments?post=1651"}],"version-history":[{"count":1,"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/posts\/1651\/revisions"}],"predecessor-version":[{"id":1652,"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/posts\/1651\/revisions\/1652"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/media\/1623"}],"wp:attachment":[{"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/media?parent=1651"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/categories?post=1651"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/tags?post=1651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}